Can abiraterone acetate improve outcomes for metastatic prostate cancer? a large Real-World study investigates
NCT ID NCT07721532
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study observes how abiraterone acetate tablets work in real-world settings for Chinese men with metastatic prostate cancer. Researchers will track safety, side effects, and effectiveness, including PSA levels and survival. The goal is to understand how well the drug performs outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- abiraterone acetate tablets
- What this could lead to
- If successful, this study could provide real-world evidence on the safety and effectiveness of abiraterone acetate for metastatic prostate cancer, potentially guiding treatment decisions.
- What could go wrong
- As an observational study, it does not test a new treatment but collects data on existing use. Results may be influenced by patient selection and lack of a control group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIAGNOSED WITH METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Drum Tower Hospital
Nanjing, China